Economic Reporter :
On December 1, 2016, the United Nations-backed public health organization, the Medicines Patent Pool (MPP) on December 1 announced the expansion of its network of generic manufacturers to Bangladesh by including Beximco Pharma for producing the Bristol-Myers Squibb’s new hepatitis C drug daclatasvir (originator brand Daclinza) under a sub-licensing arrangement, said a press release.
Through the agreement, Beximco Pharma becomes the first Bangladeshi company to achieve this unique feat following a thorough review done by the MPP.
Daclatasvir is direct-acting antiviral that can cure all major genotypes of the HCV virus. The drug received regulatory approval in Europe in August 2014 and it was included in the new WHO Model List of Essential Medicines in April 2015.
In November 2015, MPP announced a licence and technology transfer agreement with Bristol-Myers Squibb (BMS) to increase access to DCV in low- and middle-income countries.
On joining the MPP’s prestigious network of generic suppliers, Managing Director of Beximco Pharma Nazmul Hassan MP said “We are glad to be a part of this global network as the first Bangladeshi company and we believe our competitive cost of production will help improve access to this new and highly effective hepatitis C treatment for patients in many low- and middle-income countries.”
MPP is working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with governments, industry, civil society, international organisations, patient groups and other stakeholders to forecast, prioritise and license needed medicines. The organisation encourages generic manufacture and the development of new formulations through patent pooling. MPP is now working with fifteen generic companies on more than 100 projects to manufacture, register and deliver 13 World Health Organization-recommended HIV and hepatitis C treatments to up to 131 countries in the developing world.
As of now, daclatasvir has been sub-licensed to Sandoz, Aurobindo, Cipla, Emcure, Hetero, Laurus, Natco Pharma Ltd and Zydus Cadila.
On December 1, 2016, the United Nations-backed public health organization, the Medicines Patent Pool (MPP) on December 1 announced the expansion of its network of generic manufacturers to Bangladesh by including Beximco Pharma for producing the Bristol-Myers Squibb’s new hepatitis C drug daclatasvir (originator brand Daclinza) under a sub-licensing arrangement, said a press release.
Through the agreement, Beximco Pharma becomes the first Bangladeshi company to achieve this unique feat following a thorough review done by the MPP.
Daclatasvir is direct-acting antiviral that can cure all major genotypes of the HCV virus. The drug received regulatory approval in Europe in August 2014 and it was included in the new WHO Model List of Essential Medicines in April 2015.
In November 2015, MPP announced a licence and technology transfer agreement with Bristol-Myers Squibb (BMS) to increase access to DCV in low- and middle-income countries.
On joining the MPP’s prestigious network of generic suppliers, Managing Director of Beximco Pharma Nazmul Hassan MP said “We are glad to be a part of this global network as the first Bangladeshi company and we believe our competitive cost of production will help improve access to this new and highly effective hepatitis C treatment for patients in many low- and middle-income countries.”
MPP is working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with governments, industry, civil society, international organisations, patient groups and other stakeholders to forecast, prioritise and license needed medicines. The organisation encourages generic manufacture and the development of new formulations through patent pooling. MPP is now working with fifteen generic companies on more than 100 projects to manufacture, register and deliver 13 World Health Organization-recommended HIV and hepatitis C treatments to up to 131 countries in the developing world.
As of now, daclatasvir has been sub-licensed to Sandoz, Aurobindo, Cipla, Emcure, Hetero, Laurus, Natco Pharma Ltd and Zydus Cadila.
